Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

Blood

Volumn 118, Issue 12, 2011, Pages 3263-3272

  Piconi, Stefania ^a   Parisotto, Serena ^b   Rizzardini, Giuliano ^a   Passerini, Simone ^a   Terzi, Roberta ^a   Argenteri, Barbara ^a   Meraviglia, Paola ^a   Capetti, Amedeo ^a   Biasin, Mara ^b   Trabattoni, Daria ^b   Clerici, Mario ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HYDROXYCHLOROQUINE; KI 67 ANTIGEN; MESSENGER RNA; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

EID: 80053203528     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329060     Document Type: Article

References (47)

1. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine by hydroxychloroquine: inhibition of interleukin- 1 alpha (IL-1 alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20(5):803-808. (Pubitemid 23158473)
2. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokines release into human whole blood. Am J Physiol. 1998;274:R1058-R1064.
3. Popert AJ, Mejers KA, Sharp J, Bier F. Chloroquine diphosphate in rheumatoid arthritis: a controlled trial. Ann Rheum Dis. 1961;20:18-24.
4. Tsokos GC. Immunomodulatory treatment in patients with rheumatic disease: mechanisms of action. Semin Arthritis Rheum. 1987;17(1):24-38. (Pubitemid 17135783)
5. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988;85(4A):62-67.
6. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 suppl 1):82-91.
7. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol. 1981;90(3):656-664. (Pubitemid 12254921)
8. Hong Z, Jiang Z, Liangxi W, et al. Choroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol. 2004;4(2):223-234. (Pubitemid 38296351)
9. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses. 1993;9(1):91-98. (Pubitemid 23055136)
10. Pazmiño NH, Yuhas JM, Tennani RW. Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine. Int J Cancer. 1974;14(3): 379-389.
11. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanism of inhibition and spectrum of activity. AIDS. 2001;15(17): 2221-2229. (Pubitemid 34059828)
12. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes AIDS Res Hum Retrovirus. 1993;9(1):91-98.
13. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun. 1996;226(1):1-7. (Pubitemid 26332155)
14. Naarding MA, Baan E, Pollakis G, Paxon WA. Effects of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007;4:6-18.
15. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4): 622-636.
16. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther. 1997;19:913-923. (Pubitemid 27508927)
17. Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide and didanosine as economic treatment for HIV-1. Lancet. 2002; 359(9318):1667-1668. (Pubitemid 34518528)
18. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T cell activation. Antimicrob Agents Chemother. 2010;54(2): 871-881.
19. Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation during chronic HIV infection with chloroquine therapy. J Virol. 2010; 84(22):12082-12086.
20. French MA, King MS, Tschampa JM, Da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200(8): 1212-1215.
21. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371. (Pubitemid 44924494)
22. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor ligands induce human T-cell activation and death, a model for HIV pathogenesis. PLoS One. 2008;3(4):e1915.
23. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis. 2005;191(10):1670-1679. (Pubitemid 40656755)
24. Pitrak DL, Bolanos J, Hershow R, Novak RM. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS. 2001; 15(10):1317-1319. (Pubitemid 32592369)
25. Marchetti G, Bellistri GM, Borghi E, at al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035-2038.
26. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virologic responses to HAART. AIDS. 2006;20(13):1727-1736. (Pubitemid 44299364)
27. Ostrowski SR, Katzenstein TL, Thim PT, Petdersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1 infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005; 191(3):348-357. (Pubitemid 40139759)
28. Chun TW, Shawn Justement TL, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis. 2002;185(11):1672-1676. (Pubitemid 34587533)
29. García F, Vidal C, Plana M, et al. Residual lowlevel viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2000;30(2):392-394. (Pubitemid 30131553)
30. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunological effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS. 1998;12(14):1833-1844. (Pubitemid 28454449)
31. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type-1 infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003; 77(20):11212-11219. (Pubitemid 37204311)
32. Sabbatini F, Bandera A, Ferrario G, et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLoS One. 2010;5(11): e14119.
33. Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010; 24(13):1991-2000.
34. Clerici M, Stocks NI, Zajac RA, et al. Interleukin-2 production used to detect antigenic peptide recognition of HIV synthetic peptides recognition by T helper lymphocytes from asymptomatic HIVseropositive individuals. Nature. 1989;339:383-386.
35. Saresella M, Marventano I, Longhi R, et al. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008;22(10):3500-3508.
36. Biasin M, Piacentini L, Lo Caputo S, et al. TLR activation pathways in HIV-1-exposed seronegative individuals. J Immunol. 2010;184(5):2710-2717.
37. Oswald-Richter K, Grill SM, Shariat N, et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004;2:E198.
38. Apoil PA, Puissant B, Roubinet F, et al. FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr. 2005;39:381-385. (Pubitemid 41003779)
39. Kinter AL, Hennessey M, Bell A, et al. CD25+CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004;200(3):331-343. (Pubitemid 39031252)
40. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197(4):403-411. (Pubitemid 36278597)
41. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 2001; 8(4):906-912.
42. López CB, García-Sastre A, Williams BR, Moran TM. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negativestrand RNA viruses. J Infect Dis. 2003;187(7): 1126-1136. (Pubitemid 36399354)
43. Siegal FP, Lopez C, Fitzgerald PA, et al. Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest. 1986;78(1):115-123. (Pubitemid 16068189)
44. Donaghy H, Pozniak A, Gazzard B, et al. Loss of blood CD11c+ myeloid and CD11c- plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001;98(8):2574-2576.
45. Almeida M, Cordero M, Almeida J, Orfao A. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS. 2005;19(3):261-271. (Pubitemid 40396557)
46. Kamga I, Kahi S, Develioglu L, et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis. 2005;192(2):303-310. (Pubitemid 40993400)
47. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010;54(2): 871-881.